Halma plc (LSE:HLMA) is assessed against its Main Market market context and its core business in safety, environmental and health technology businesses.
NIOX Group plc (LSE:NIOX) is being assessed through the lens of its healthcare exposure and its ability to turn strategic plans into measurable operating performance.
The modest decline follows a dramatic recovery in the shares. Oxford Nanopore closed at around 122p on 18 August, the day before its interim results, and has since rallied by roughly 70%. Some profit-taking after such a strong move is not surprising.
IXICO raised its expected annual revenue after analysis orders accelerated towards the end of its financial year. Expected revenue exceeded the guidance already increased during the summer. The year-end order book grew, and the expected adjusted operating loss improved relative to market expectations despite …
The September interim update described continued development of P140 and Kapiglucagon following the earlier fundraising. P140 remains a prospective autoimmune licensing asset, with a companion-diagnostic approach intended to improve patient selection. Kapiglucagon development includes specialist manufacturing and bioanalytical work. These are separate programmes with …
RUA Life Sciences Plc (LSE:RUA) is assessed against its AIM market context and its core business in medical-device technologies and biomaterials development.
Tristel plc (LSE:TSTL) is assessed against its AIM market context and its core business in infection-prevention products for medical devices and healthcare surfaces.
The immediate question for holders of ImmuPharma plc (LSE:IMM) is whether renewed trading interest reflects durable improvements in fundamentals or a short-lived change in positioning. Share-price gains can arise from earnings releases, operational announcements, investor flows or thin liquidity. These explanations should not be …
The immediate question for holders of Ondine Biomedical, Inc. (LSE:OBI) is whether renewed trading interest reflects durable improvements in fundamentals or a short-lived change in positioning. Share-price gains can arise from earnings releases, operational announcements, investor flows or thin liquidity. These explanations should not …
The immediate question for holders of Bioventix Plc (LSE:BVXP) is whether renewed trading interest reflects durable improvements in fundamentals or a short-lived change in positioning. Share-price gains can arise from earnings releases, operational announcements, investor flows or thin liquidity. These explanations should not be …